New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri^® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.